Mentorship in Pulmonary Vascular Disease

肺血管疾病的指导

• 批准号: 10542767
• 负责人: Anna R Hemnes
• 金额: $ 11.46万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-01-01 至 2026-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10542767
• 关键词: Affect; Award; Basic Science; Bioinformatics; Blood Vessels; Career Mobility; Cessation of life; Classification; Clinic; Clinical; Clinical Research; Clinical Trials; Data; Development; Diagnosis; Disease; Disease Marker; Educational workshop; Faculty; Funding; Goals; Grant; Guidelines; Human; Institution; Insulin Resistance; International; Intervention; Lipids; Lung; Lung diseases; Measures; Mentors; Mentorship; Metabolic; Metabolic Diseases; Metabolic dysfunction; Metformin; Mid-Career Clinical Scientist Award (K24); Midcareer Investigator Award in Patient-Oriented Research; Molecular; National Heart, Lung, and Blood Institute; Outcome; Pathogenesis; Patients; Phenotype; Postdoctoral Fellow; Predisposition; Productivity; Program Research Project Grants; Prospective cohort; Publications; Pulmonary Hypertension; Recording of previous events; Research; Research Personnel; Research Project Grants; Research Training; Resources; Right Ventricular Dysfunction; Scientist; Severity of illness; Techniques; Testing; Time; Training; United States; United States National Institutes of Health; Work; career; career development; clinical phenotype; cohort; effective therapy; experience; improved; large datasets; member; molecular phenotype; mortality; next generation; novel therapeutics; patient oriented; patient oriented research; precision medicine; programs; pulmonary arterial hypertension; pulmonary vascular disorder; recruit; resilience; response; right ventricular failure; skills; student mentoring; training opportunity; treatment response; treatment strategy; working group

Pulmonary arterial hypertension (PAH) is a rare lung disease characterized by progressive pulmonary vascular obliteration resulting in right ventricular failure and ultimately death. Throughout the last three decades there has been tremendous progress in understanding disease mechanisms that have led to new therapies, however survival remains poor at approximately 8 years after diagnosis for most patients. There have been several recent NIH/NHLBI sponsored workshops on phenotyping patients with PAH and moving accumulating “Omic” data into the clinic to advance precision medicine in PAH, yet there are few centers in where this work is ongoing and training the next generation of researchers in these techniques will be critically important to advancing the field of PAH therapy and pulmonary vascular disease more broadly. Dr. Hemnes is a well- recognized expert in this field and her objective is to use the support of the K24 Midcareer Investigator Award in Patient-Oriented Research to focus on training the next generation of scientists to bring precision medicine approaches to PAH patient therapy. The candidate’s immediate and long-term career objectives are directly in line with the goals of the NIH K24 award, to provide support for protected time for awardees to devote to patient-oriented research and culturally-sensitive mentoring for students, residents, fellows and junior faculty. Specifically, this award will allow her to focus on the development of (1) a patient-oriented research program in pulmonary vascular disease research and (2) a mentoring program to facilitate the career development of new investigators. This award will provide protected time for the candidate to devote specifically to developing mentoring skills in patient-oriented research. Her objective is to recruit and mentor students, residents, fellows and junior faculty for successful clinical research careers in pulmonary vascular disease and to support the career advancement of her current trainees who are fellows and junior faculty members. To expand her patient-oriented research program in PAH, she will combine two lines of study in her research portfolio (1) understanding how insulin resistance in the lipid axis may predispose to PAH or affect outcomes and (2) using Omic techniques to deep phenotype patients with pulmonary vascular disease. The proposal here will build on her funded work to test the hypothesis that Omic signatures in PAH can identify features of resilience to PAH progression and metabolic intervention susceptibility. The specific aims are (1) To compare PAH patients with and without Omic signatures of metabolic dysfunction, define differences in clinical and molecular features and measure relevant outcomes between the two groups, (2) To test and validate Omic predictors of metformin responses in completed and ongoing clinical trials in PAH patients. Completion of these aims will enhance understanding of the pathogenesis of PAH and uncover potentially improved treatment strategies of metabolic disease in PAH specifically. The proposed new research, along with the candidate’s other funded research projects, will provide invaluable training opportunities in patient-oriented pulmonary vascular disease research.

肺动脉高压（PAH）是一种罕见的肺部疾病，其特征是进行性肺血管 闭塞导致正确的心室衰竭并最终导致死亡。在过去的三十年中 在理解导致新疗法的疾病机制方面取得了巨大进展，但是 大多数患者诊断后大约8年的生存率仍然很差。有几个 最近的NIH/NHLBI赞助了有关PAH患者表型和移动累积“ OMIC”的讲习班 进入诊所的数据以促进PAH的精密医学，但在这项工作的中心很少 持续和培训这些技术的下一代研究人员对 更广泛地推进PAH疗法和肺血管疾病领域。 Hemnes博士是一个很好的 该领域的公认专家，她的目标是使用K24中级研究员奖的支持 在以患者为导向的研究中，专注于培训下一代科学家以携带精密医学 PAH患者疗法的方法。候选人的直接和长期职业目标直接存在 与NIH K24奖的目标保持一致，以为获奖者提供支持的时间 针对学生，居民，研究员和初级教师的注重患者的研究和对文化敏感的心理。 具体而言，该奖项将使她能够专注于（1）以患者为导向的研究计划 肺血管疾病研究和（2）一个心理计划，旨在促进新的职业发展 调查人员。该奖项将为候选人提供专门发展的保护时间 指导面向患者的研究技能。她的目标是招募和指导学生，居民，研究员 和肺部血管疾病成功临床研究事业的初级教师 她目前的学员和初级教师的职业发展。扩大她 在PAH中以患者为导向的研究计划，她将在研究组合中结合两条研究（1） 了解脂质轴中的胰岛素耐药性如何易于PAH或影响结果，以及（2） 肺血管疾病的深度表型患者的浮膜技术。这里的提议将基于 她资助的工作以检验以下假设，即PAH中的OMIC签名可以识别出对PAH的弹性特征 进展和代谢干预敏感性。具体目的是（1）将PAH患者与 并且如果没有代谢功能障碍的绝对特征，则定义了临床和分子特征的差异 测量两组之间的相关结果，（2）以测试和验证二甲双胍的OMIC预测指标 PAH患者的完整和正在进行的临床试验的反应。这些目标的完成将增强 了解PAH的发病机理并发现了代谢的潜在改进的治疗策略 PAH中的疾病。拟议的新研究以及候选人的其他资助研究 项目将在面向患者的肺血管疾病研究中提供宝贵的培训机会。